The News Fact Service,
New Delhi, May 18,
Covaxin, manufactured by Bharat Biotech and ICMR, has been approved by the Drug Controller General of India in its second and third phase trials. Kovaxin will start its trial between 2 to 18 years of age in the next 10 to 12 days. Bharat Biotech will conduct this trial on 525 healthy volunteers. This information was given by Dr. VK Paul, Health Member of NITI Aayog on Tuesday. India, which is battling the second wave of Corona, preparations have started to save the children from the third wave. It is being said that in the corona havoc, its third wave will affect the most children.
This concern also increases because there is not even a single vaccine in the country for children. But now there is news of relief that soon the vaccine will be available for children in India because the vaccine is ready for trial. The Expert Committee recommended clinical trials for the second/third stage of Bharat Biotech’s Kovid-19 vaccine covaxin for ages 2 to 18. It is being told that this test will be done at various places including AIIMS in Delhi and Patna and Meditrina Institute of Medical Sciences, Nagpur. Bharat Biotech will conduct this test with 525 healthy volunteers. Significantly, in the midst of the corona epidemic, vaccination is being done in the country at a rapid pace.